Morning Briefing
Summaries of health policy coverage from major news organizations
Research Roundup: The Latest Science, Discoveries, And Breakthroughs
The Guardian: Scientists Create Mice With Part-Human Brains
Researchers hope to shed light on conditions such as schizophrenia, epilepsy, cerebral palsy, intellectual disability and rare forms of dementia. (Sample, 9/16)
Medical Xpress: Blood Test Shows Promise For Detecting Pancreatic Cancer At Its Earliest Stages
A large international study, published in Nature Medicine today, found that a liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. (9/16)
Medical Xpress: Gut Microbiome Features Predict Devastating Disease Affecting Preemies
In a discovery that challenges long-standing assumptions about necrotizing enterocolitis, a sudden and often fatal intestinal illness that affects premature infants, researchers at Washington University School of Medicine in St. Louis have identified previously unknown predictors for the disease. (9/16)
Medical Xpress: Epstein-Barr Virus Activity May Foreshadow Multiple Sclerosis Attacks
In a study of blood samples from more than 100 participants with MS, Mass General Brigham researchers detected increased EBV lytic activity in immune cells up to three months before MS relapse and discovered that these cells also showed elevated expression of genes linked to MS risk. (9/16)
Medical Xpress: Gut Supplement Shows Promise Against Opioid-Related Damage In Rat Pups
New UNSW research published in Translational Psychiatry shows a gut supplement can repair opioid-related damage in rat pups, raising hopes for a future treatment for babies exposed to opioids in the womb. (9/16)
MedPage Today: Real-World U.S. Data Back Azithromycin After Unscheduled C-Sections
Use of adjunctive azithromycin increased among women undergoing unscheduled cesarean deliveries and postpartum infection rates fell after a landmark trial showed the antibiotic's benefits in this setting, according to a difference-in-differences analysis. (Rudd, 9/14)
FiercePharma: GSK Prepares Frontline FDA Bid For Jideytro, Its First Lung Cancer Drug
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate. (Liu, 9/13)
Stat: Definium’s LSD Therapy Shows Positive Effect On Anxiety In Trial
Definium Therapeutics said Monday that its LSD therapy helped patients with anxiety in a second late-stage trial, setting up the company to seek the first approval of a psychedelic drug for anxiety. (Chen, 9/14)
Stat: Vera Kidney Drug Trutakna Shows Strong Final Results In Phase 3 Trial
Vera Therapeutics said Tuesday that its recently approved drug Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in patients with a chronic autoimmune kidney disease, according to final, two-year results from a Phase 3 clinical trial. (Feuerstein, 9/15)
